Jw. Finney et Sc. Monahan, THE COST-EFFECTIVENESS OF TREATMENT FOR ALCOHOLISM - A 2ND APPROXIMATION, Journal of studies on alcohol, 57(3), 1996, pp. 229-243
Objective: This review builds on the innovative research synthesis of
Holder and his colleagues, addresses some of the limitations of the bo
x-score approach to assessing treatment effectiveness that they used a
nd provides a second approximation of the cost-effectiveness of treatm
ent for alcoholism. Method: For each of 141 comparative treatment stud
ies, we determined whether or not it found at least one statistically
significant positive effect on a drinking-related outcome variable for
each of the modalities examined in a paired contrast with one other c
ondition. We next calculated the predicted probability of each study y
ielding at least one statistically significant treatment effect, based
on the number of tests for treatment effects conducted. Following tha
t, for each study of a particular treatment modality, the strength of
the ''weakest competitor'' against which the modality had been compare
d was determined. For each modality, we used the average predicted pro
bability of the relevant studies finding a significant effect and the
average effectiveness of the weakest competitor to predict the modalit
y's effectiveness. Results: We calculated an Adjusted Effectiveness In
dex (AEIn) for each modality, which was the difference between its pre
dicted and actual effectiveness score. Our AEIn results were consisten
t with those of Holder et al. in suggesting that some of the same moda
lities appear to be effective or ineffective. Our results differed fro
m their findings with respect to other modalities, however. Using data
presented by Holder and his colleagues on the minimum estimated cost
of providing different modalities, we offer a second approximation of
the modalities' cost-effectiveness. Conclusions: Overall, we found a s
maller range of effectiveness across modalities than did Holder and hi
s colleagues and a non-significant relationship between cost and effec
tiveness. Like Holder et al., we do not believe major treatment provis
ion or funding decisions should be based solely on this type of review
.